{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:21:39Z","timestamp":1794298899301,"version":"4.9.0"},"reference-count":35,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T00:00:00Z","timestamp":1663459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Amyloid"],"published-print":{"date-parts":[[2023,1,2]]},"DOI":"10.1080\/13506129.2022.2118043","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T04:37:17Z","timestamp":1663562237000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial"],"prefix":"10.1080","volume":"30","author":[{"given":"Dianna","family":"Quan","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Colorado Anschutz","place":["Aurora, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Obici","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-2373","authenticated-orcid":false,"given":"John L.","family":"Berk","sequence":"additional","affiliation":[{"name":"Amyloidosis Center, Boston Medical Center","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University","place":["Kumamoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Aldinc","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"White","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-4108","authenticated-orcid":false,"given":"David","family":"Adams","sequence":"additional","affiliation":[{"name":"Neurology Department, APHP, CHU Bic\u00eatre, Universit\u00e9 Paris-Saclay, U1195, INSERM, Neurology Department, AP-HP, CHU Bic\u00eatre","place":["Le Kremlin Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,18]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-013-0182-4"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2013.06.051"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001870"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1068949"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-015-9613-9"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs123"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.754348"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-31"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-018-0514-2"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/msj.21352"},{"key":"e_1_3_4_14_1","unstructured":"Amyloidosis Research Consortium. The voice of the patient report \u2013 amyloidosis. 2016. Available from: https:\/\/www.arci.org\/wp-content\/uploads\/2018\/05\/Voice-of-the-Patient.pdf accessed July 22 2022."},{"key":"e_1_3_4_15_1","unstructured":"Duncan D. With hope for a cure. 2018. Available from: http:\/\/amyloidosis.org\/proactive-3\/ accessed July 22 2022."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24519"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612470192"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143590"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0210-4"},{"key":"e_1_3_4_20_1","unstructured":"swissmedic. Abbreviated information for health care professionals for ONPATTRO 10\u2009mg\/5\u2009ml concentrate for solution for infusion (version September 2019). 2022. Available from: www.swissmedicinfo.ch accessed July 22 2022."},{"key":"e_1_3_4_21_1","unstructured":"European Medicines Agency. Summary of product characteristics: Onpattro 2\u2009mg\/mL concentrate for solution for infusion. 2018. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/onpattro-epar-product-information_en.pdf accessed July 22 2022."},{"key":"e_1_3_4_22_1","unstructured":"Alnylam announces approval in Brazil of ONPATTRO\u00ae for the treatment of hereditary ATTR amyloidosis with polyneuropathy [Internet]. Alnylam Pharmaceuticals Inc. 2020. Available from: https:\/\/investors.alnylam.com\/press-release?id=24606 accessed July 22 2022."},{"key":"e_1_3_4_23_1","unstructured":"Alnylam announces approval in Japan of ONPATTRO\u00ae for the treatment of hereditary ATTR amyloidosis with polyneuropathy [Internet]. Alnylam Pharmaceuticals Inc ; 2019. Available from: https:\/\/investors.alnylam.com\/press-release?id=23886 accessed July 22 2022."},{"key":"e_1_3_4_24_1","unstructured":"Alnylam Pharmaceuticals Inc. US prescribing information: ONPATTRO (patisiran) lipid complex injection for intravenous use. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210922s007lbl.pdf accessed July 22 2022."},{"key":"e_1_3_4_25_1","unstructured":"CADTH. Patisiran. 2019. Available from: https:\/\/www.cadth.ca\/patisiran accessed July 22 2022."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0948-5"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.06.041"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318208824b"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns5.12059"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13510"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1503593"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.04.001"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30368-9"},{"key":"e_1_3_4_34_1","volume-title":"Global open-label extension: 24-month data of patisiran in patients with hATTR amyloidosis","author":"Adams D","year":"2020","unstructured":"Adams D, Gonzalez Duarte A, Mauricio E, et\u00a0al. Global open-label extension: 24-month data of patisiran in patients with hATTR amyloidosis. Peripheral Nerve Society (PNS) Congress; June 27\u201330 2020. Miami, FL, USA."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1357545"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14285"}],"container-title":["Amyloid"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13506129.2022.2118043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:27:14Z","timestamp":1747747634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13506129.2022.2118043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,18]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,2]]}},"alternative-id":["10.1080\/13506129.2022.2118043"],"URL":"https:\/\/doi.org\/10.1080\/13506129.2022.2118043","relation":{},"ISSN":["1350-6129","1744-2818"],"issn-type":[{"value":"1350-6129","type":"print"},{"value":"1744-2818","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iamy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iamy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}